Novo is best known for the insulins and other diabetes medicines its scientists spent years developing and refining. Deals for drugs invented outside its laboratories are relatively rare, as are agreements focused on diseases other than the metabolic condition.
But Novo has shown an interest in expanding its research into blood disease and cardiovascular treatments, mounting a failed bid for the Belgian drugmaker Ablynx in 2018 and, more recently, acquiring Corvidia Therapeutics and its antibody drug for heart disease.
The deal for Prothena’s PRX004, though a bit further afield, appears to fit into that pattern, giving Novo a mid-stage therapy for a disease that’s receiving more and more attention from drugmakers. READ MORE
By Ned Pagliarulo
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.